Novo Nordisk advances early-stage obesity medication, amycretin, to phase 3 clinical development based on early-phase clinical trial results in people with obesity or excess weight, published in The Lancet
Both subcutaneous and oral formulations will advance straight to phase 3 development based on completed clinical studies and feedback received from regulatory authorities1,2
PLAINSBORO, N.J., June 20, 2025 /PRNewswire/ -- Today, results from two early-phase clinical trials evaluating Novo Nordisk's amycretin, an innovative investigational obesity treatment designed to target appetite regulation, were published in The Lancet.1 In a phase 1b/2a clinical trial of 125 adults with overweight or obesity, once-weekly subcutaneous amycretin appeared to be safe and tolerable in trial participants, who also achieved significantly greater weight loss across the full range of doses investigated versus placebo.1 A related phase 1 trial of once-daily oral amycretin in adults with obesity or overweight also showed that treatment was safe and tolerable with an observed reduction in body weight compared to placebo.2 No weight loss plateau was observed in either trial at the end of the respective treatment durations.1,2 Data on subcutaneous amycretin is scheduled to be presented on Sunday, June 22nd, during a late-breaking poster session at the American Diabetes Association's® (ADA) 85th Scientific Sessions.1
"We are pleased with the promising results of amycretin and the feedback from regulatory authorities and are excited to advance both subcutaneous and oral versions of this molecule into phase 3 development for weight management. At Novo Nordisk, we understand that addressing obesity is a complex challenge that many patients face. These results reflect our robust pipeline in obesity, our focus on progressing scientific innovation and expanding the range of options available to patients and healthcare professionals," said Martin Holst Lange, executive vice president for Development at Novo Nordisk. "We remain steadfast in our mission to discover and develop therapies that can have a meaningful impact in the lives of those affected by obesity."
Results from the phase 1b/2a trial of subcutaneous amycretin showed treatment-emergent adverse events (TEAEs) were mild or moderate in severity and increased in frequency in a dose-dependent manner. The most frequent reported TEAEs were gastrointestinal in nature. Compared to placebo, participants receiving amycretin observed greater weight loss across the full range of doses investigated.1 Subcutaneous amycretin at multiple doses demonstrated greater weight reduction than placebo at the end of the trial. Participants who received the highest doses (up to 60 mg) reported body weight reductions of up to 24.3% versus 1.1% with placebo after 36 weeks of treatment. Results from this first-in-human phase 1b/2a study support further investigation of potential weight-loss efficacy of amycretin.
Results from the published phase 1 trial of oral amycretin showed that the most common TEAEs were related to gastrointestinal symptoms (mainly nausea and vomiting) and decreased appetite; these were most frequent for the higher doses. Trial participants receiving the study treatment demonstrated significantly greater weight loss across the full range of doses investigated versus the placebo group.2 Exploratory results showed participants taking 100 mg per day of oral amycretin achieved a mean weight loss of 13.1% versus 1.2% with placebo after 12 weeks.2 Based on these phase 1 results, longer evaluation with more participants is warranted to substantiate the full efficacy findings of oral amycretin on body weight reductions and changes in metabolic parameters.
Novo Nordisk will advance both subcutaneous and oral amycretin formulations straight to phase 3 development for weight management based on these and other completed clinical studies, as well as feedback received from regulatory authorities.
About amycretinAmycretin is a unimolecular long-acting GLP-1 and amylin receptor agonist under development by Novo Nordisk, to provide a treatment for adults with overweight or obesity and as a treatment for adults with type 2 diabetes. Amycretin is under investigation for oral and subcutaneous administration, and is not approved in the US for weight loss.
About the phase 1b/2a subcutaneous amycretin trialThe phase 1b/2a trial was a randomized, placebo-controlled, single-center, double-blinded study of 125 participants assessing the safety, tolerability, pharmacokinetics, and effects on body weight after subcutaneous administration of amycretin in people with overweight or obesity.1 Adults with a body mass index of 27-39.9kg/m2 and glycated hemoglobin (HbA1c) <6.5% were eligible for the trial.1 The trial was conducted in 5 parts: a single ascending dose (Part A) for determination of pharmacokinetics and starting dose for the first multiple dose cohort in which the safety and tolerability were explored using dose escalation until 36 weeks of total treatment duration (Part B).1 Lastly, in the multiple ascending dose – dose response parts, body weight loss was explored for up to 36 weeks of dosing by escalating to dose levels of 1.25 mg, 5 mg, and 20 mg, respectively, dosed for 12 weeks (Part E, D and C).1
About the phase 1 oral amycretin trial The phase 1 single-center, randomized, placebo-controlled study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses (Part A) and multiple ascending doses (Part B, 10 days of treatment; Part C/D, 12 weeks of treatment) of 144 adult participants with overweight or obesity.2 The primary endpoint was the number of treatment-emergent adverse events (TEAEs) observed in the trial. The trial evaluated the single-ascending dose and multiple ascending doses for oral amycretin, up to 2 times 50 mg, in people with overweight or obesity, with a total treatment duration of up to 12 weeks.2
About obesityObesity is a serious chronic, progressive, and complex disease that requires long-term management.3-5 One key misunderstanding is that this is a disease of just lack of willpower, when in fact there is underlying biology that may impede people with obesity from losing weight and keeping it off.3,5 Obesity is influenced by a variety of factors, including genetics, social determinants of health, and the environment.6,7
The prevalence of overweight and obesity is a public health issue that has severe cost implications to healthcare systems.8,9 In the US, about 40% of adults live with obesity.10
About Novo NordiskNovo Nordisk is a leading global healthcare company that's been making innovative medicines to help people with diabetes lead longer, healthier lives for more than 100 years. This heritage has given us experience and capabilities that also enable us to drive change to help people defeat other serious chronic diseases such as obesity, rare blood, and endocrine disorders. We remain steadfast in our conviction that the formula for lasting success is to stay focused, think long-term, and do business in a financially, socially, and environmentally responsible way. With a US presence spanning 40 years, Novo Nordisk US is headquartered in New Jersey and employs over 10,000 people throughout the country across 12 manufacturing, R&D and corporate locations in eight states plus Washington DC. For more information, visit novonordisk-us.com, Facebook, Instagram, and X.
Novo Nordisk is committed to the responsible use of our semaglutide-containing medicines which represent distinct products with different indications, dosages, prescribing information, titration schedules, and delivery forms. These products are not interchangeable and should not be used outside of their approved indications. Learn more at semaglutide.com.
Contacts for further information
Media:Liz Skrbkova (US)+1 609 917 0632USMediaRelations@novonordisk.com
Ambre James-Brown (Global)+45 3079 9289Globalmedia@novonordisk.com
Investors:Frederik Taylor Pitter (US)+1 609 613 0568fptr@novonordisk.com
Jacob Martin Wiborg Rode (Global)+45 3075 5956jrde@novonordisk.com
Sina Meyer (Global)+45 3079 6656 azey@novonordisk.com
Ida Schaap Melvold (Global)+45 3077 5649 idmg@novonordisk.com
Max Ung (Global)+45 3077 6414mxun@novonordisk.com
References
Dahl K, Toubro S, Dey S, et al. Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: Results of a randomised, controlled, phase 1b/2a study. The Lancet. Published online: June 20, 2025.
Gasiorek A, Heydorn A, Gabery S, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, randomised, placebo-controlled study. The Lancet. Published online: June 20, 2025.
Kaplan LM, Golden A, Jinnett K, et al. Perceptions of barriers to effective obesity care: results from the national action study. Obesity. 2018;26(1):61-69.
Bray GA, Kim KK, Wilding JPH; World Obesity Federation. Obesity: a chronic relapsing progressive disease process. A position statement of the World Obesity Federation. Rev. 2017;18(7):715-723.
Garvey WT, Mechanick JI, Brett EM, et al. American association of clinical endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22 (Suppl 3):1-203.
Centers for Disease Control and Prevention. Adult obesity facts. Last accessed: June 2025. Available at: https://www.cdc.gov/obesity/adult-obesity-facts/index.html.
World Obesity Federation. World Obesity Atlas 2023. Last accessed: June 2025. Available at: https://www.worldobesity.org/resources/resource-library/world-obesity-atlas-2023.
Centers for Disease Control and Prevention. Risk Factors for Obesity. Last accessed: June 2025. Available at: https://www.cdc.gov/obesity/risk-factors/risk-factors.html.
Centers for Disease Control and Prevention. Why it matters. Last accessed: June 2025. Available at: https://www.cdc.gov/obesity/php/about/?CDC_AAref_Val=https://www.cdc.gov/obesity/about-obesity/why-it-matters.html.
Centers for Disease Control and Prevention. Obesity and Severe Obesity Prevalence in Adults: United States, August 2021–August 2023. Last accessed June 2025. Available at: https://www.cdc.gov/nchs/products/databriefs/db508.htm.
© 2025 Novo Nordisk All rights reserved. US25SEMO01477 June 2025
View original content to download multimedia:https://www.prnewswire.com/news-releases/novo-nordisk-advances-early-stage-obesity-medication-amycretin-to-phase-3-clinical-development-based-on-early-phase-clinical-trial-results-in-people-with-obesity-or-excess-weight-published-in-the-lancet-302487500.html
SOURCE NOVO NORDISK INC.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
Zeke Cohen calls for Baltimore City Council hearing on behavioral crisis response
Baltimore City Council President Zeke Cohen wants the city to take a closer look at behavioral health crisis response issues by adding another hearing to the council's busy oversight schedule this summer. Cohen's request comes after three people experiencing behavioral health crises died in an eight-day period this month. June 17: Bilal Yusuf-Muhammad 'B.J.' Abdullah Jr, 36, was shot and killed after exchanging gunfire with Baltimore Police Department officers near the Upton subway station. June 24: An unidentified man approached a police cruiser stopped at West Franklin Street and North Franklintown Road and walked repeatedly into the middle of the road. An officer tried to restrain the man and called for EMS, but the man became unresponsive before they arrived and died at a hospital hours later, according to the Maryland Office of the Attorney General. June 25: Police shot and killed Pytorcarcha Brooks, 70, on Mosher Street. Police said Brooks brandished a knife and lunged at one officer before another officer at the scene fired his weapon. 'These tragedies are a heartbreaking reminder that far too many Baltimoreans suffer in silence,' Cohen said in a statement Friday.'Today I am calling for a hearing in the City Council's Public Safety Committee to examine our behavioral health crisis response systems.' Councilman Mark Conway, who chairs the Public Safety Committee, has sought to hold council hearings on the city's opioid crisis — an epidemic with clear ties to the behavioral health challenges facing Baltimore. The council's upcoming schedule includes hearings related to the opioid crisis on July 9 and July 16, but they will be taken up by the Public Health & Environment Committee. Conway's advocacy on the opioid crisis put him at odds with Mayor Brandon Scott, who argued earlier this year that holding public hearings would jeopardize Baltimore's ongoing legal efforts to hold pharmaceutical companies responsible for distributing drugs in the city. The city has already secured more than $400 million in settlements, though a judge ruled that jurors last November awarded Baltimore 'grossly excessive' compensation from pharmaceutical titans McKesson and AmerisourceBergen. This case remains ongoing and could be headed for a retrial if the city does not accept the decision that reduced jurors' original verdict by more than $200 million. Other notable oversight hearings on the council's upcoming schedule include transportation (July 10), crime reduction/violence prevention (July 15), psychiatric rehabilitation programs (July 23), and recovery homes/substance abuse clinics (July 30). Have a news tip? Contact Carson Swick at cswick@
CBS News
29 minutes ago
- CBS News
Shedd Aquarium's beluga whale Kimalu to have cyst removal surgery
A beluga whale at the Shedd Aquarium is getting help while dealing with a rare medical condition. Kimalu has been at the Shedd for 12 years. The animal health and care teams at the aquarium noticed she was dealing with bumps that turned out to be cysts. Doctor Karisa Tang, vice president of animal health, said they will perform surgery to examine them and, if possible, remove some, while also preparing for any issues. "Anytime you sedate or anesthetize an animal, you run the risk they may not recover," she said. "This is especially true for belugas because of their unique physiology as large, deep-sea swimmers and voluntary breathers." The center didn't share the exact day of the surgery but said it would post updates when it knows more.
Yahoo
29 minutes ago
- Yahoo
Is Running Really THAT Bad On Your Knees? The Answer May Surprise You.
You're probably familiar with the idea that running is bad for your knees. It's a pervasive thought that keeps many folks from going out for a jog. Some people say running is hard on your joints while others say the impact can cause arthritis. Is this true? Or is running just a fitness regimen with a bad rap? Thanks to recent research, doctors now have a more full view of running's impact on the knees (and other joints). Below, doctors shared with HuffPost their thoughts on whether running is safe for your knees. 'Anybody that already has arthritis or any other type of medical condition or orthopedic problem should probably consult with their doctor to ensure that running is safe for them,' said Dr. Jeffrey Fleming, a sports medicine physician at the University of Pittsburgh Medical Center and the medical director of the Pittsburgh Marathon. There are lots of restrictions and symptoms associated with arthritis and injuries, and they vary greatly from person to person. 'We want to make sure that we're treating each individual person appropriately,' Fleming said. If you notice sharp pain or even a dull pain in the joints after each run, you should see a doctor before you continue your running regimen, added Dr. A.J. Monseau, an emergency medicine and sports medicine physician at West Virginia University. This way, a doctor can figure out what is going on before a larger issue happens. 'I think there's good evidence at this point that running can actually improve cartilage health to some extent, as long as we are not injuring ourselves,' Monseau said. Healthy cartilage allows your joints and bones to function properly and in a painless manner by lubricating the joints and absorbing the shock that happens when you move around. This way, your bones don't directly feel the impact. Running can also 'help strengthen the muscles and the bones around the knees,' according to Dr. Sean Thompson, an orthopedic surgeon and owner of East Coast Bone and Joint Surgeons. '[Running] can help prevent osteoporosis by increasing bone density,' Thompson shows that exercise like running can help build strong bones. Folks with osteoporosis have weak or brittle bones because of a loss of bone density. It's particularly common in women who are postmenopausal. The loss of estrogen that happens in menopause can also cause a loss of bone density. As Thompson mentioned, exercise, particularly before menopause (but during menopause is valuable, too), can help build up bone density and give folks higher levels of bone density when the estrogen loss does begin. A common misconception is that running can lead to knee arthritis, but experts say that isn't accurate. 'If you look at the most recent research that we have on this subject, the short answer to that question is we don't think that running causes arthritis in your knees,' Fleming said. Some evidence even shows that recreational runners are sometimes less likely to develop arthritis when compared to non-runners, Fleming said, but added that it's unclear if it's the running that leads to a less arthritis incidence or the healthier lifestyle that's often followed by runners,such as a healthier diet and a dedicated workout regimen. 'Strengthening the muscles around the knee, like the quads or the gluteal ... muscles, and especially the core muscles, can help to prevent injury from running, especially when you're first starting,' Thompson said. This aligns with the activity recommendations from the American College of Sports Medicine, which recommend strength and resistance training in addition to cardiovascular exercise, said Monseau. If you haven't exercised for some time or are nervous about potential joint pain, there are a few things you can do to decrease the risk of pain. First, you should consider doing a warm-up. 'That is a completely personal thing. If your body and your knees and your hips and everything feel good after a rather gentle warm-up for even a few minutes, that's probably sufficient for you, but some people find that they need longer time of warming up before they really get after it,' said Monseau. You should also start training gradually, said Fleming. Meaning, if you are a new runner who's training for a half-marathon, you shouldn't go out and try to run 5 miles without building up. 'We often see people develop injuries whenever they start preparing for a marathon, and often it's because they're doing too much too soon,' Fleming said. 'The other big thing that can help prevent injury or help prevent arthritis is just making sure that you're using an appropriate running form and you have the appropriate equipment — you have a decent pair of running shoes,' said Fleming. 'These are all pretty simple things, but if you overlook them, and you run in a way that doesn't support these things, you can definitely develop some pain and have a greater risk for injury and arthritis down the line.' You can talk to anyone from a sports medicine physician to personal trainer to physical therapist about proper running form and proper running gear. Many towns even have dedicated running stores you can visit for shoe fittings and advice. Running on softer surfaces such as a track or on the grass can be a good option, said Thompson. Research shows that there's less impact on your joints when running on these kinds of surfaces. 'If there are limitations that don't allow the individual to run, even walking at a brisk pace or incline walking can show similar benefits to running,' Thompson said. 'The general rule of thumb that I often tell people is movement is so important for overall health, and I'm not very picky in terms of what type of movement you go out and get, whether that's running or cycling or weightlifting, just as long as you're doing something,' said Fleming. 'So, if running is something you want to do, I fully encourage you to give it a try, as long as it'll help you move more,' he added. Beyond the benefit to your joint health, running is also good for your mental health and your cardiovascular health. Plus, regular physical activity (like running) can lower your risk of dementia and certain cancers. So, the benefits of running on your health potentially outweigh any of the joint or arthritis risks you hear about, Fleming said. Running Experts Reveal The Foods They Avoid For A Poop-Free Run 'Rucking' Is The Latest Walking Trend You Need To Try. Here's Why. Study Reveals How Much Exercise Older Adults Need Each Week To Live Longer
